Press Resease

Kidney Fibrosis Treatment Market - By Therapeutics (Angiotensin II Receptor Blockers, Angiotensin Converting Enzyme Inhibitors, Renin Inhibitors, Pirfenidone, and Vasopeptidase Inhibitors), By Location Of Testing (Commercial/Private Hospitals, Hospital Testing, Clinics, Public Health Hospitals, and Home Treatment), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Published Date: 13-Jan-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2989 Status : Published

The global Kidney Fibrosis Treatment market, which accrued revenue worth nearly 4 (USD Billion) in 2018 and is slated to garner earnings worth 12 (USD Billion) by 2025, is set to grow at a CAGR of 4.5% during the period from 2019 to 2025.

Description

The global Kidney Fibrosis Treatment market, which accrued revenue worth nearly 4 (USD Billion) in 2018 and is slated to garner earnings worth 12 (USD Billion) by 2025, is set to grow at a CAGR of 4.5% during the period from 2019 to 2025. The report offers valuation and analysis of the Kidney Fibrosis Treatment market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. The report offers historical data from 2015 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion).

Introduction

Kidney fibrosis is caused as a result of excess gathering of extracellular matrix and symbolizes a failure of wound healing procedure of tissues of kidney. In addition to this, kidney fibrosis is a method that results in end-stage renal disorder. Rising cases of chronic kidney disorders and kidney fibrosis along with rise in the patient population base has resulted in the need for kidney fibrosis treatment in the recent years. In addition to this, renal fibrosis results in particular damage or disorder of kidney. Diabetes, heart problems, and family history of chronic kidney disorder are few of the causes of kidney fibrosis.

Market Growth Drivers

Escalating occurrence of chronic disorders due to unhealthy food habits has resulted in kidney fibrosis cases, thereby culminating into huge market demand in the upcoming years. Surge in the aging population along with massive awareness pertaining to renal fibrosis therapy will prompt the kidney fibrosis market expansion over the forthcoming years. Rise in the frequency of obesity with changing food patterns has resulted in increase in kidney problems, thereby driving the market earnings.

Moreover, rise in health consciousness among the various age-groups of population will culminate into massive market penetration across the globe over the upcoming years. Nonetheless, strict laws pertaining to approval of kidney fibrosis therapy may put brakes on the industry growth over the forecast timeframe.

North America To Erupt As Global Market Leader During Forecast Timeframe

The expansion of kidney fibrosis treatment market in North America over the estimated timeframe is attributed to surge in the population base suffering from kidney ailments. In addition to this, rise in the launching of end-stage kidney disorder therapy in the country such as the U.S. will provide lucrative growth avenues for kidney fibrosis treatment market in North America over the assessment period. Rise in the CRO activities and surge in the healthcare spending in the U.S. and Canada has further added to the expansion of the market in the region. As per CDC, nearly 37 million adult populations were slated to have been affected due to chronic kidney ailments during 2019. This accounted for 15% of total adult population in the U.S.  Apart from this, CDC has reported that in the U.S. children above the age of 18 suffer from polycystic kidney disorder and glomerulonephritis. All these aforementioned factors will drive the demand for kidney fibrosis therapy in the U.S., thereby driving the regional market trends.

Key participants profiled in the report are InterMune Inc., Merck & Co., Pfizer Inc., La Jolla Pharmaceutical Company, F. Hoffman-La Roche Ltd., Galectin Therapeutics, BioLine Rx Ltd., Genzyme Corporation, and ProMetic Life-Sciences Inc.

The global kidney fibrosis treatment market is segmented as follows:

By therapeutics:

  • Angiotensin II receptor blockers (ARBs)
  • Angiotensin Converting Enzyme (ACE) inhibitors
  • Pirfenidone
  • Renin Inhibitors
  • Vasopeptidase Inhibitors

By location of testing:

  • Public health hospitals
  • Hospital testing
  • Commercial/private hospitals
  • Clinics
  • Home Treatment

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodulogy
  • Chapter 2. Executive Summary
    • 2.1. Kidney Fibrosis Treatment Market, 2015–2025 (USD Billion)
    • 2.2. Kidney Fibrosis Treatment Market: Snapshot
  • Chapter 3. Global Kidney Fibrosis Treatment Market– Industry Analysis
    • 3.1. Kidney Fibrosis Treatment Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Escalating occurrence of chronic disorders due to unhealthy food habits has resulted in kidney fibrosis cases, thereby culminating into huge market demand in the upcoming years.
      • 3.2.2. Surge in the aging population along with massive awareness pertaining to renal fibrosis therapy will prompt the kidney fibrosis market expansion over the forthcoming years.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Therapeutics
      • 3.4.2. Market attractiveness analysis By Material
  • Chapter 4. Global Kidney Fibrosis Treatment Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Kidney Fibrosis Treatment Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Kidney Fibrosis Treatment Market– Therapeutics Analysis
    • 5.1. Global Kidney Fibrosis Treatment Market overview: By Therapeutics
      • 5.1.1. Global Kidney Fibrosis Treatment Market share, By Therapeutics , 2019 and 2025
    • 5.2. Angiotensin II Receptor Blockers
      • 5.2.1. Global Kidney Fibrosis Treatment Market By Angiotensin II Receptor Blockers , 2015–2025 (USD Billion)
    • 5.3. Angiotensin Converting Enzyme Inhibitors
      • 5.3.1. Global Kidney Fibrosis Treatment Market By Angiotensin Converting Enzyme Inhibitors, 2015–2025 (USD Billion)
    • 5.4. Renin Inhibitors
      • 5.4.1. Global Kidney Fibrosis Treatment Market By Renin Inhibitors , 2015–2025 (USD Billion)
    • 5.5. Pirfenidone
      • 5.5.1. Global Kidney Fibrosis Treatment MarketBy Pirfenidone, 2015–2025 (USD Billion)
    • 5.6. Vasopeptidase Inhibitors
      • 5.6.1. Global Kidney Fibrosis Treatment MarketBy Vasopeptidase Inhibitors, 2015–2025 (USD Billion)
  • Chapter 6. Global Kidney Fibrosis Treatment Market– Location of Testing Analysis
    • 6.1. Global Kidney Fibrosis Treatment Market overview: By Location of Testing
      • 6.1.1. Global Kidney Fibrosis Treatment Market share, By Location of Testing , 2019 and 2025
    • 6.2. Commercial/Private Hospitals
      • 6.2.1. Global Kidney Fibrosis Treatment Market By Commercial/Private Hospitals, 2015–2025 (USD Billion)
    • 6.3. Hospital Testing
      • 6.3.1. Global Kidney Fibrosis Treatment Market By Hospital Testing, 2015–2025 (USD Billion)
    • 6.4. Clinics
      • 6.4.1.1. Global Kidney Fibrosis Treatment Market By Clinics, 2015–2025 (USD Billion)
    • 6.5. Public Health Hospitals
      • 6.5.1.1. Global Kidney Fibrosis Treatment Market By Public Health Hospitals, 2015–2025 (USD Billion)
    • 6.6. Home Treatment
      • 6.6.1.1. Global Kidney Fibrosis Treatment Market By Home Treatment, 2015–2025 (USD Billion)
  • Chapter 7. Company Profiles
    • 7.1. F. Hoffman-La Roche Ltd.
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Service Portfulio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Merck & Co.
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Service Portfulio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Galectin Therapeutics
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Service Portfulio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Pfizer Inc.
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Service Portfulio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. InterMune Inc.
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Service Portfulio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. La Julla Pharmaceutical Company
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Service Portfulio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Genzyme Corporation
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Service Portfulio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. ProMetic Life-Sciences Inc.
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Service Portfulio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. BioLine Rx Ltd
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Service Portfulio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development

Methodology


Frequently Asked Questions

Escalating occurrence of chronic disorders due to unhealthy food habits has resulted in kidney fibrosis cases, thereby culminating into huge market demand in the upcoming years. Surge in the aging population along with massive awareness pertaining to renal fibrosis therapy will prompt the kidney fibrosis market expansion over the forthcoming years. Rise in the frequency of obesity with changing food patterns has resulted in increase in kidney problems, thereby driving the market earnings. Moreover, rise in health consciousness among the various age-groups of population will culminate into massive market penetration across the globe over the upcoming years.

 

According to Zion market research, the global Kidney Fibrosis Treatment market, which accrued revenue worth nearly 4 (USD Billion) in 2018 and is slated to garner earnings worth 12 (USD Billion) by 2025, is set to grow at a CAGR of 4.5% during the period from 2019 to 2025.

North America is likely to make remarkable contributions towards overall market size during 2019-2025. The surge in the expansion of market in the sub-continent over the estimated timespan is due to surge in the population base suffering from kidney ailments. In addition to this, rise in the launching of end-stage kidney disorder therapy in the country such as the U.S. will provide lucrative growth avenues for kidney fibrosis treatment market in North America over the assessment period. Rise in the CRO activities and surge in the healthcare spending in the U.S. and Canada has further added to the expansion of the market in the region. As per CDC, nearly 37 million adult populations were slated to have been affected due to chronic kidney ailments during 2019. This accounted for 15% of total adult population in the U.S.  Apart from this, CDC has reported that in the U.S. children above the age of 18 suffer from polycystic kidney disorder and glomerulonephritis. All these aforementioned factors will drive the demand for kidney fibrosis therapy in the U.S., thereby driving the regional market trends.

 

The key players profiled in the report include InterMune Inc., Merck & Co., Pfizer Inc., La Jolla Pharmaceutical Company, F. Hoffman-La Roche Ltd., Galectin Therapeutics, BioLine Rx Ltd., Genzyme Corporation, and ProMetic Life-Sciences Inc.
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social